GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » Accumulated other comprehensive income (loss)

Revance Therapeutics (STU:RTI) Accumulated other comprehensive income (loss) : €0.1 Mil (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Revance Therapeutics Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Revance Therapeutics's Accumulated other comprehensive income (loss) for the quarter that ended in Sep. 2024 was €0.1 Mil.

Revance Therapeutics's quarterly Accumulated other comprehensive income (loss) declined from Mar. 2024 (€-0.0 Mil) to Jun. 2024 (€-0.0 Mil) but then increased from Jun. 2024 (€-0.0 Mil) to Sep. 2024 (€0.1 Mil).

Revance Therapeutics's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 (€-0.0 Mil) to Dec. 2022 (€-0.4 Mil) but then increased from Dec. 2022 (€-0.4 Mil) to Dec. 2023 (€0.0 Mil).

Revance Therapeutics Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Revance Therapeutics's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Accumulated other comprehensive income (loss) Chart

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.02 -0.35 0.01

Revance Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.01 -0.02 -0.02 0.07

Revance Therapeutics Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Revance Therapeutics Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
TERN OABI RGNX RIGL AURA ENGN CMPX ALMS CDXS MBX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 ONC
Traded in Other Exchanges
N/A
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Website
https://www.revance.com
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics Headlines

No Headlines